# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Partnership Will Provide Cell and Gene Therapy Industry with Fully Integrated Logistics and Manufacturing Services for Regenera...
Needham analyst David Saxon reiterates CryoPort (NASDAQ:CYRX) with a Buy and maintains $18 price target.
CryoPort (NASDAQ:CYRX) reported quarterly losses of $(0.43) per share which missed the analyst consensus estimate of $(0.35) by...